Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Kim Conlin

Physician Assistant Bozeman, MT Physician Assistant

NPI 1497065072 CMS profile 10827117

1648 Ellis St Ste 201, Bozeman, MT 59715

Open in the dashboard

General payments

$2,086

91 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kim Conlin of Bozeman, MT is reported in the CMS Open Payments database as having received $2,086 across 91 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $632 24
2024 General $753 31
2023 General $690 35
2022 General $12 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kim Conlin
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Kim Conlin were reported at $632. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Kim Conlin Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $12 $155 $48–$522 $149
2023 $690 $167 $52–$557 $160
2024 $753 $178 $55–$600 $164
2025 $632 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Janssen Biotech, Inc. $445 28 payments
  2. Boston Scientific Corporation $353 8 payments
  3. Lilly USA, LLC $279 14 payments
  4. Merck Sharp & Dohme Corporation $186 8 payments
  5. AstraZeneca Pharmaceuticals LP $184 7 payments
  6. Stemline Therapeutics Inc. $114 4 payments
  7. Penumbra, Inc. $90 1 payment
  8. Servier Pharmaceuticals LLC $88 4 payments
  9. Regeneron Healthcare Solutions, Inc. $72 2 payments
  10. Seattle Genetics, Inc. $68 3 payments
  11. Other $207 12 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,086 91 payments
Products named General payments · program years 2022–2025
  1. VERZENIO $234 12 payments
  2. EMBOLD Fibered $225 6 payments
  3. DARZALEX $201 12 payments
  4. KEYTRUDA $186 8 payments
  5. TECVAYLI $143 8 payments
  6. RETEVMO $122 6 payments
  7. JAYPIRCA $118 6 payments
  8. Orserdu $114 4 payments
  9. ERLEADA $91 7 payments
  10. Indigo System $90 1 payment
  11. Other $972 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$17,151

Medicare's payments for the services billed

Medicare patients

158

Average age 75

Services billed

326

89 women, 69 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 69%
Arthritis 48%
Cancer 30%
Chronic kidney disease 27%
Diabetes 26%
Ischemic heart disease 26%
Atrial fibrillation 26%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $59
$59 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $38
  • AstraZeneca Pharmaceuticals LP $15
$53 — —
VERZENIO
  • Lilly USA, LLC $49
$49 — —
RYBREVANT
  • Janssen Biotech, Inc. $40
$40 — —
Orserdu
  • Stemline Therapeutics Inc. $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

91 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Montana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record